Dr. Reddy's Laboratories Limited (DRREDDY) — Corporate Action

1 Corporate Action 🔴 High Importance Neutral 📄 PDF

No summary available

2 Corporate Action 🔴 High Importance Neutral 📄 PDF

📢 Key Event
Dr. Reddy's Laboratories proposed a final dividend of ₹8 per share for FY26, to be paid after AGM approval on July 23, 2026.

🔄 What Changed
Recommended final dividend of ₹8/share; disclosed Rs 4,530 million lenalidomide shelf stock adjustment, Rs 1,350 million CAR-T R&D impairment, and Rs 1,141 million VAT provision; FY26 revenue grew 3.2% YoY to Rs 335,933 million; gross margin at 52.8%, EBITDA margin at 22.8%; employee costs increased by Rs 1,170 million due to New Labour Codes.

🔮 What's Next
AGM scheduled for July 23, 2026, where shareholder approval of dividend and director appointments is required.

💡 Investor Takeaway
Shareholders will receive a dividend yield of approximately 2.5% based on current market price, subject to AGM approval.

Dr. Reddy's Laboratories announced a recommended final dividend of ₹8 per share (800% face value) for FY26, with the record date set for July 10, 2026, and the AGM scheduled for July 23, 2026, where shareholder approval is required. The Board reappointed independent directors including Dr. K P Krishnan and appointed Srikanth Velamakanni as an Additional Director, while Deloitte was reappointed as statutory auditor. The filing disclosed significant financial impacts including a Rs 4,530 million lenalidomide shelf stock adjustment, Rs 1,350 million CAR-T R&D impairment, and Rs 1,141 million VAT provision, contributing to a 11.6% YoY revenue decline in Q4FY26. Despite this, FY26 revenue grew 3.2% YoY to Rs 335,933 million, with gross margin at 52.8% and EBITDA margin at 22.8%. The company also recognized one-time gains of Rs 877 million and increased employee costs by Rs 1,170 million due to New Labour Codes. Shareholders will receive a dividend yield of approximately 2.5% based on current market price, subject to AGM approval.

📊 Stock Analysis — DRREDDY ✨ Ask AI About This